The peptides development was ultimately discontinued in 2007 after a 24-week Phase III trial failed to demonstrate statistically significant weight loss compared to placebo, though research into its regenerative properties has continued
A friend in a peptide research group mentioned adding AOD-9604 to her protocol, and after reading up on how it targets fat cells directly, I decided to try it
In some research contexts, observations have included mild and transient tolerability-related effects such as: Headaches Nausea Stimulation-related observations Temporary injection-site irritation or localized skin-response variability Research conditions, concentration ranges, dosage ranges, hydration status, administration frequency, and protocol structure may influence tolerability observations across experimental settings
The exact amount depends on the patients health, how bad the deficiency is, and how well they respond to treatment